A Third Shot at EGFR: New Opportunities in Cancer Therapy-Reference-Cited by-同舟云学术

A Third Shot at EGFR: New Opportunities in Cancer Therapy

Published:2019-12 Issue:12 Volume:40 Page:941-955
ISSN:0165-6147
Container-title:Trends in Pharmacological Sciences
language:en
Short-container-title:Trends in Pharmacological Sciences

Author:

Guardiola Salvador,Varese Monica,Sánchez-Navarro Macarena,Giralt Ernest

Funder

MINECO-FEDER

Generalitat de Catalunya

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference122 articles.

1. The EGFR family: not so prototypical receptor tyrosine kinases;Lemmon;Cold Spring Harb. Perspect. Biol.,2014

2. EGF–ERBB signalling: towards the systems level;Citri;Nat. Rev. Mol. Cell Biol.,2006

4. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence;Troiani;ESMO Open,2016

5. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression;Ohsaki;Oncol. Rep.,2000

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and mechanistic insight of novel imidazolones as potential EGFR inhibitors and apoptosis inducers;Bioorganic Chemistry;2024-03

2. Niosomes as promising approach for enhancing the cytotoxicity of Hemimycale sp. total crude extract supported with in-silico studies;Scientific Reports;2024-01-31

3. Computational analysis of bevacizumab binding with protein receptors for its potential anticancer activity;Journal of Biomolecular Structure and Dynamics;2024-01-28

4. Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study;Frontiers in Oncology;2024-01-16

5. Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression;Biomaterials Science;2024